Actively Recruiting
Synovial Proliferation on Routine Ultrasound: Active or Inactive?
Led by Van Creveldkliniek · Updated on 2026-05-05
46
Participants Needed
1
Research Sites
147 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
There is cumulating evidence for the presence of non-observed or subclinical joint bleeding in patients with haemophilia. Early detection of active subclinical synovial proliferation would allow early intervention in order to prevent deterioration of joint health. Patients with subclinical (=non-observed) signs of synovial proliferation in knee(s), ankle(s) and/or elbow(s) will be invited to participate in this study to further characterize the synovial proliferation status (active or inactive) by means of physical examination, MRI, ultrasound and elastography. Synovial proliferation status will be monitored for a maximum period of 12 weeks, during which participants will also receive standard-of-care treatment, i.e. administration of optimized coagulation factor replacement therapy and prescription of the NSAID celecoxib (optional).
CONDITIONS
Official Title
Synovial Proliferation on Routine Ultrasound: Active or Inactive?
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male gender
- Diagnosis of severe haemophilia A or B
- Receiving registered prophylaxis medication including coagulation factors or by-passing agents
- Age 12 years or older
- Presence of subclinical synovial proliferation in at least one joint (ankle, knee, or elbow) confirmed by routine ultrasound using HEAD-US protocol
- Able to provide written informed consent
You will not qualify if you...
- Major joint bleed within 3 months or minor joint bleed within 1 month before study entry in the joint of interest
- Receiving on-demand therapy instead of prophylaxis
- Currently not receiving any haemophilia prophylaxis medication
- Joints with prosthesis or treated with arthrodesis are excluded from examination and ultrasound analysis
- Confirmed inflammatory joint diseases such as rheumatoid arthritis or psoriatic arthritis
- History of inhibitor development (≥5 Bethesda Units at any time or 1-5 BU for 1 year before inclusion)
- Contraindications for NSAIDs, including allergy, severe liver failure, renal failure (GFR <30 ml/min), congestive heart failure (NYHA II-IV), peripheral arterial disease, or cerebrovascular disease
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University Medical Center Utrecht
Utrecht, Netherlands, 3584CX
Actively Recruiting
Research Team
L
Lize van Vulpen, MD, PhD
CONTACT
M
Merel Timmer, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here